Skip to main
LH

LH Stock Forecast & Price Target

LH Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Labcorp Holdings demonstrates strong financial performance, evidenced by a 7.5% revenue increase in its Central Lab segment, primarily driven by significant trial wins and the introduction of advanced digital pathology and AI solutions. Additionally, the Diagnostic segment recorded solid revenue growth of 8.9% year-over-year, supported by both organic growth and acquisitions contributing equally to this increase. Furthermore, the company showcases robust operational metrics with a backlog of $8.71 billion, reflecting a 10% year-over-year improvement and a net book-to-bill ratio of 1.11x, indicating positive momentum and demand for its services.

Bears say

The financial outlook for Labcorp Holdings is negatively influenced by several key risks, including adverse shifts in reimbursement policies under the Protecting Access to Medicare Act (PAMA) and challenges related to the integration of acquisitions. Additionally, increased competition and economic uncertainty further exacerbate the company's financial stability, potentially impacting revenue growth. Although total requisitions showed a modest increase of 4.9%, this figure fell short of the anticipated growth of 5.2%, highlighting potential weaknesses in organic volume performance and overall market positioning.

LH has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Labcorp Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Labcorp Holdings Inc (LH) Forecast

Analysts have given LH a Buy based on their latest research and market trends.

According to 12 analysts, LH has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $301.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $301.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Labcorp Holdings Inc (LH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.